Vera Therapeutics, Inc. (VERA)
NASDAQ: VERA · Real-Time Price · USD
39.65
+0.35 (0.89%)
At close: Mar 4, 2026, 4:00 PM EST
39.26
-0.39 (-0.98%)
Pre-market: Mar 5, 2026, 5:24 AM EST
Vera Therapeutics Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Vera Therapeutics stock have an average target of 80.56, with a low estimate of 33 and a high estimate of 110. The average target predicts an increase of 103.18% from the current stock price of 39.65.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Vera Therapeutics stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 5 | 5 | 5 | 4 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 11 | 11 | 11 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $90 → $110 | Strong Buy | Maintains | $90 → $110 | +177.43% | Mar 2, 2026 |
| B of A Securities | B of A Securities | Strong Buy Maintains $48 → $66 | Strong Buy | Maintains | $48 → $66 | +66.46% | Dec 19, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $55 → $95 | Strong Buy | Maintains | $55 → $95 | +139.60% | Dec 19, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $99 → $96 | Buy | Maintains | $99 → $96 | +142.12% | Dec 19, 2025 |
| Wedbush | Wedbush | Hold Maintains $23 → $33 | Hold | Maintains | $23 → $33 | -16.77% | Dec 11, 2025 |
Financial Forecast
Revenue This Year
45.42M
Revenue Next Year
247.69M
from 45.42M
Increased by 445.28%
EPS This Year
-4.76
from -4.66
EPS Next Year
-3.29
from -4.76
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 128.8M | 495.4M | |||
| Avg | 45.4M | 247.7M | |||
| Low | 12.7M | 135.6M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | 990.6% | |||
| Avg | - | 445.3% | |||
| Low | - | 198.5% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -3.34 | 0.88 | |||
| Avg | -4.76 | -3.29 | |||
| Low | -5.93 | -5.11 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.